Recent Updates
Recently added Catalysts

Pruritus: two biotech companies racing to a treatment

Immunology & InflammationConcentrated betData as of 2026-09-04

Competitors2in the clinic
Median market cap$1.6Buniverse median $1.20B
Allocated capital$1.2B$3.3B competing
Phase 3 or filed02 mid, 0 early
Pure plays1this indication only
Capital rank133/299crowding rank 90

Pruritus is a two-horse race: Celldex Therapeutics (CLDX, $3.1B) against Canton Strategic Holdings (CNTN, $174M).

A duopoly prices differently from an empty field. Each company is the other's comparable, so a readout from either side repositions both, and $1.2B of allocated capital sits on the pair.

CLDX alone accounts for 95% of the $3.3B of market capitalisation competing here, so this is a leader plus a tail rather than a level race.

$1.2B of allocated capital sits in Pruritus, 133rd of 299 indications, and 1 of the 2 companies are pure plays that trade on this indication alone.

Companies developing drugs for Pruritus 2

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
CLDXCelldex TherapeuticsBarzolvolimabPhase 21$3.1BNo3 31 Oct 2026
CNTNCanton Strategic HoldingsNalmefenePhase 21$174MYes1No dated event

Sorted by phase, then by market capitalisation. Ticker links open the company profile. CLDX holds 95% of the $3.3B competing in this indication.

Why Pruritus is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Pruritus has 2 competitors and a median of $1.6B.

Immunology & Inflammation

Immunology & Inflammation holds $139B of the map's capital, 20.7% of the total, spread across 51 indications and 82 companies. 23 of those indications have more than one company competing.

See every Immunology & Inflammation indication on the map

Related indications in Immunology & Inflammation

Eosinophilic Esophagitis2 companies · $1.2B · median $610MOrphan cornerModerate to Severe Atopic Dermatitis1 company · $1.3B · median $2.6BUncontestedAutoimmune Pulmonary Alveolar Proteinosis1 company · $1.1B · median $1.1BUncontestedChronic Spontaneous Urticaria1 company · $1.0B · median $3.1BUncontestedPeanut Allergy1 company · $861M · median $861MUncontestedImmunoglobulin A Nephropathy1 company · $1.6B · median $6.3BUncontestedCeliac Disease1 company · $788M · median $1.6BUncontestedANCA-associated Vasculitis2 companies · $1.7B · median $3.3BConcentrated bet

Pruritus pipeline questions

Which biotech companies are developing drugs for Pruritus?

Celldex Therapeutics (CLDX, Barzolvolimab, Phase 2); Canton Strategic Holdings (CNTN, Nalmefene, Phase 2). Those are the 2 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Pruritus.

How advanced is the Pruritus pipeline?

Of the 2 clinical-stage programmes in Pruritus, 0 are in Phase 3 or filed, 2 are in mid-stage development and 0 are in early-stage development.

Which company leads the Pruritus field?

CLDX is the largest developer in Pruritus, holding 95% of the $3.3B of market capitalisation competing in the indication. The median competitor is worth $1.6B.

When is the next Pruritus catalyst?

The next dated catalyst in Pruritus is CLDX on 31 Oct 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map